Background-We have previously reported the safety and effectiveness of sirolimus-eluting stents for the treatment of de novo coronary lesions. The present investigation explored the potential of this technology to treat in-stent restenosis. Methods and Results-Twenty-five patients with in-stent restenosis were successfully treated with the implantation of 1 or 2 sirolimus-eluting Bx VELOCITY stents in São Paulo, Brazil. Nine patients received 2 stents (1.4 stents per lesion). Angiographic and volumetric intravascular ultrasound (IVUS) images were obtained after the procedure and at 4 and 12 months. All vessels were patent at the time of 12-month angiography. Angiographic late loss averaged 0.07Ϯ0.2 mm in-stent and Ϫ0.05Ϯ0.3 mm in-lesion at 4 months, and 0.36Ϯ0.46 mm in-stent and 0.16Ϯ0.42 mm in-lesion after 12 months. No patient had in-stent or stent margin restenosis at 4 months, and only one patient developed in-stent restenosis at 1-year follow-up. Intimal hyperplasia by 3-dimensional IVUS was 0.92Ϯ1.9 mm 3 at 4 months and 2.55Ϯ4.9 mm 3 after 1 year. Percent volume obstruction was 0.81Ϯ1.7% and 1.76Ϯ3.4% at the 4-and 12-month follow-up, respectively. There was no evidence of stent malapposition either acutely or in the follow-up IVUS images, and there were no deaths, stent thromboses, or repeat revascularizations. Conclusion-This study demonstrates the safety and the potential utility of sirolimus-eluting Bx VELOCITY stents for the treatment of in-stent restenosis. (Circulation. 2003;107:24-27.) 
T reating in-stent restenosis (ISR) has become one of the major challenges for the interventional cardiologist. 1 Regardless of which percutaneous approach is chosen to treat an in-stent restenotic lesion (balloon angioplasty, stent, rotational atherectomy, or laser angioplasty), 30% to 80% of the patients will develop restenosis within the stent, at the stent edges, or both. Currently, the only proven effective therapy available for patients with ISR is intravascular brachytherapy. 2 Unfortunately, this complex therapy carries with it the risks associated with ionizing radiation, including delayed endothelialization and potential late vascular thrombosis. 3 The first-in-man (FIM) study has recently demonstrated the safety and effectiveness of sirolimus-eluting Bx VELOC-ITY stents for the treatment of single, de novo coronary lesions. 4, 5 In this somewhat benign population, no major clinical events (thrombosis, repeat revascularization, myocardial infarction, or death) occurred within 1-year of follow-up. Twelve months after the index procedure, neointimal prolif-eration and late lumen loss were virtually absent as determined both by quantitative intravascular ultrasound (IVUS) and angiography. Subsequently, the multicenter RAndomized study with the sirolimus-eluting Bx VELocity balloonexpandable stent (RAVEL) study corroborated these results by reporting the absence of restenosis 6 months after the implantation of sirolimus-eluting stents in a similar subset of patients with de novo, single vessel, coronary artery disease. 6 Whether such unparalleled results would be replicated in a more complex patient group, such as those with ISR, remains to be determined.
The aims of this pilot study were to determine the feasibility and safety of treating ISR with slow-release sirolimuseluting Bx VELOCITY stents and to determine the impact of this technology on prevention of recurrent restenosis.
Methods
From March to June of 2001, 25 consecutive patients with ISR were successfully treated with the implantation of the sirolimus-eluting Bx VELOCITY stent. Stents were coated with 140 g sirolimus/cm 2 per unit of metal surface area. The slow release formulation (Ն28-day drug release) was used in this protocol. 4, 5 Patients were excluded if they had undergone previous intravascular radiation therapy to the target vessel, if the index lesion was Ͼ36 mm in length, or if the lesion was located in a saphenous vein graft.
Procedure
All stents were 18 mm long and varied from 2.5 to 3.5 mm in diameter. There was no ostial lesion treated in the present investigation. After predilatation of the target lesion, stents were deployed with high-pressure (Ͼ14 atmospheres) postdilatation, guided by IVUS to assure complete stent expansion, which was defined as in-stent minimal lumen area Ͼ80% of reference lumen area, and apposition. Debulking devices were not used, and predilatation was performed with conventional balloon. The operator was allowed to implant up to 2 sirolimus-eluting stents to cover the entire length of the lesion, but coverage of the entire stented segment was not mandatory. Overlapping of the 2 adjacent sirolimus-eluting stents was recommended per the protocol. All patients received aspirin (325 mg/d, indefinitely) commencing at least 12 hours before the procedure and clopidogrel 300 mg immediately after stent implantation and 75 mg/d for 60 days thereafter. The protocol was approved by the Medical Ethical Committee and informed consent was obtained for every patient.
Quantitative Measurements
Postprocedure and 4-and 12-month quantitative coronary angiography (QCA) and IVUS imaging were performed in all patients. IVUS images were acquired using a motorized pullback at a constant speed of 0.5 mm/sec and volumetric quantification was performed. Quantitative angiographic and volumetric IVUS analyses were performed by independent Core laboratories (Brigham and Women's Hospital, Boston, Mass and Cardialysis B.V, Rotterdam, The Netherlands, respectively). The three segments selected for volumetric IVUS analysis were the segment covered by sirolimus-eluting stents and 2 edge segments (axially 5 mm proximal and distal to the sirolimuseluting stent margins). The presence of intimal hyperplasia in previously deployed stents and anatomical landmarks noted by angiography during stent deployment were used to guide IVUS selection of the segment covered by sirolimus-eluting stents.
As described previously, 5 2 coronary segments were subjected to quantitative angiography, in-stent and in-lesion segments. The instent analysis encompassed only the segment covered by sirolimuseluting stent. The in-lesion segment was defined as the in-stent segment plus segments 5-mm proximal and 5-mm distal to the edge or the nearest side branch if the side branch was nearer than 5 mm from the stent edge. Contrast injection and angiography was performed after positioning the stent delivery system just before deployment. The relation between anatomic landmarks, including the previously deployed stents, and the 2 radiopaque markers of the delivery system were noted. In-stent and in-lesion restenosis were defined as Ն50% diameter stenosis (DS) at follow-up, located within the stent and target lesion, respectively. Minimal lumen diameter (MLD) and %DS were measured for each segment. In-lesion and in-stent late lumen loss (LL) were calculated as postprocedure MLD minus follow-up MLD. Validation of volumetric IVUS quantification has been described elsewhere. 7
Statistical Analysis
Continuous variables are expressed as meanϮSD. Comparisons between postintervention and follow-up measurements were performed with a 2-tailed paired t test. A probability value Ͻ0.05 was considered statistically significant.
Results
The mean age was 56Ϯ12 years; 80% of the patients were male, and 24% were diabetics. Five patients (20%) had recurrent ISR. The time interval between initial bare metal stent implantation and development of in-stent restenosis varied from 3 to 7 months. Lesions were classified as focal (Յ10 mm) in 32%, diffuse intrastent in 40%, and diffuse proliferative in 28% of the patients according to previously reported classification. 1 All stents were implanted successfully. Stent edge dissection was not detected either by angiography or IVUS and patients were discharged without complications 24 hours after treatment.
All patients were free of angina after 1 year, and there were no repeat revascularizations, stent thromboses, or major adverse clinical events (cerebrovascular accident, myocardial infarction, or death) during this time.
Angiographic data are presented in Table 1 . At 4 months, in-stent lumen diameter remained essentially unchanged from postprocedure in 50% of the cases ( Figure  1 ). Minimal angiography lumen gain observed in some patients may be explained by regression of intimal hyperplasia that was not covered with the sirolimus-eluting stent. There was a slightly but statistically significant decrease in in-stent MLD between 4 and 12 months (Table 1, Figure 1 ), whereas in-lesion MLD was essentially unchanged after 12 months (Table 1, Figure 1 ). Only 1 patient, who was asymptomatic, developed in-stent reste- 
Sousa et al Sirolimus-Eluting Stenting for In-Stent Restenosis
nosis at 12 months. IVUS imaging was not performed in this patient. IVUS analysis showed minimal neointimal hyperplasia volume (0.92Ϯ1.9 mm 3 at 4 months and 2.55Ϯ4.9 mm 3 at 12 months) in the remaining patients ( Table 2 ).
Discussion
The present study demonstrates the feasibility of using sirolimus-eluting stents for the treatment of ISR. All patients were asymptomatic, and only 1 patient developed in-stent restenosis 12 months after treatment. In-stent intimal hyperplasia was minimal in most patients (Figure 2) , and the in-lesion late loss was only 0.16-mm. Most importantly, the 12-month clinical follow-up was uneventful for all patients. A number of clinical studies have documented the challenge of treating ISR because of the high recurrence of restenosis (30% to 80%), 1, 8 which is directly related to the length of the ISR lesion and independent of device selection. Only recently has catheter-based intravascular brachytherapy become available as an effective treatment for patients with ISR. 2 Although intravascular brachytherapy trials have consistently shown a 40% to 70% reduction in re-restenosis as compared with placebo, there is still a 17% to 32% long-term failure rate for patients treated with brachytherapy. 2, 9, 10 The pioneer Scripps Coronary Radiation to Inhibit Proliferation Post Stenting (SCRIPPS) study irradiated 26 patients (62% had ISR) using the Iridium-192 gamma-source. 2 Lesion length was Ͻ10 mm in 42% of the patients. Out of the 24 patients with complete angiographic follow-up, 17% had recurrent restenosis.
In the present study, in which 68% of the patients had diffuse ISR, there was no in-stent or edge restenosis 4 months after the implantation of sirolimus-eluting stents, and only 1 patient developed restenosis at 12 months. This patient had a saphenous vein graft to the right coronary artery, and the 80% DS repeat ISR was located in the native artery distally to the site of graft anastomosis. Whether the proximity of the vein graft influenced the angiographic outcome remains to be clarified. The average change in MLD between 4 and 12 months shown by QCA was largely driven by this and one other patient who showed additional late loss (Figure 1) , rather than by a systematic increase in late loss in all 25 patients.
Although clopidogrel was given for only 60 days after the procedure, there were no silent or overt stent thromboses as assessed by angiography and IVUS at 4 and 12 months, which was a 10-month period off dual antiplatelet therapy. This is also consistent with the observations in the RAVEL study, where patients have been off dual antiplatelet agents for at least 10 months without thrombotic events. 6 This should be compared with the Ն6% late thrombosis rate observed after intracoronary radiation therapy, 3 which resulted in the recommendation for prolonged antiplatelet therapy (6 to 12 months) after brachytherapy, especially when a new stent is implanted at the time of the procedure. The outcomes of patients with ISR treated with stents covered with a polymer containing a paclitaxel derivative have been reported recently. 11 Although the results seemed promising after 6 months, 8 out of 13 patients had restenosis at 12 months and 2 patients experienced non-Q-wave myocardial infarctions due to stent occlusion. 11 The lack of a control group clearly precludes a definitive scientific assessment of the excellent outcomes observed in the present study. The lack of stent thrombosis, repeat revascularization, myocardial infarction, or death in this patient population, however, indicates that the antiproliferative and antiinflammatory actions of sirolimus 12 may provide a long-lasting antirestenosis effects after treatment of ISR lesions without the attendant risk of stent thrombosis observed with other effective treatment modalities. Longer-term follow-up will be required to determine whether the inhibition of in-stent restenosis observed in this study is sustained.
Although these data in a small cohort of patients are very encouraging, randomized controlled trials will be necessary to determine whether the reduction in late lumen loss, restenosis, and need for repeat intervention is indeed better than with brachytherapy, is sustained over several years, and can be achieved without the need for extended antiplatelet therapy. 
